<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Cancer - Breast on VitaminDWiki</title><link>//localhost:1313/categories/cancer---breast.html</link><description>Recent content in Cancer - Breast on VitaminDWiki</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Fri, 29 Mar 2024 00:00:00 +0000</lastBuildDate><atom:link href="//localhost:1313/categories/cancer---breast/index.xml" rel="self" type="application/rss+xml"/><item><title>Vitamin D needed to treat Breast Cancer varied by 70X</title><link>//localhost:1313/posts/vitamin-d-needed-to-treat-breast-cancer-varied-by-70x.html</link><pubDate>Fri, 29 Mar 2024 00:00:00 +0000</pubDate><guid>//localhost:1313/posts/vitamin-d-needed-to-treat-breast-cancer-varied-by-70x.html</guid><description>&lt;ul>
&lt;li>
&lt;p>&lt;strong>Personalized Vitamin D dosing&lt;/strong> ranged from 2,000 IU to 140,000 weekly for Breast Cancer:&lt;/p>
&lt;ul>
&lt;li>A range of 70 to 1&lt;/li>
&lt;/ul>
&lt;/li>
&lt;li>
&lt;p>Treating healthy people typically requires a range of Vitamin D of only 4 to 1&lt;/p>
&lt;/li>
&lt;li>
&lt;p>The women getting Breast Cancer treatment were clearly not uniformly unhealthy&lt;/p>
&lt;/li>
&lt;/ul>
&lt;blockquote>
&lt;/blockquote>
&lt;ul>
&lt;li>
&lt;p>The study failed to note improvement in outcomes vs women not getting Vitamin D&lt;/p>
&lt;ul>
&lt;li>Shorter treatment durations, less chemo used, less recurrence&lt;/li>
&lt;/ul>
&lt;/li>
&lt;/ul>
&lt;nav id="TableOfContents">
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>&lt;a href="#course-of-vitamin-d-levels-in-newly-diagnosed-non-metastatic-breast-cancer-patients-over-one-year-with-quarterly-controls-and-substitution">Course of Vitamin D Levels in Newly Diagnosed Non-Metastatic Breast Cancer Patients over One Year with Quarterly Controls and Substitution&lt;/a>&lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
&lt;/nav>
&lt;hr>
&lt;h4 id="course-of-vitamin-d-levels-in-newly-diagnosed-non-metastatic-breast-cancer-patients-over-one-year-with-quarterly-controls-and-substitution">Course of Vitamin D Levels in Newly Diagnosed Non-Metastatic Breast Cancer Patients over One Year with Quarterly Controls and Substitution&lt;/h4>
&lt;p>Nutrients. 2024 Mar 15;16(6):854. &lt;a href="https://doi.org/10.3390/nu16060854.">doi: 10.3390/nu16060854.&lt;/a>&lt;/p></description></item><item><title>Risk of Vitamin D deficiency with Breast Cancer: 2.7 X if normal weight, 7 X if obese (no surprise)</title><link>//localhost:1313/posts/risk-of-vitamin-d-deficiency-with-breast-cancer-27-x-if-normal-weight-7-x-if-obese-no-surprise.html</link><pubDate>Tue, 26 Mar 2024 00:00:00 +0000</pubDate><guid>//localhost:1313/posts/risk-of-vitamin-d-deficiency-with-breast-cancer-27-x-if-normal-weight-7-x-if-obese-no-surprise.html</guid><description>&lt;nav id="TableOfContents">
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>&lt;a href="#post-diagnosis-serum-25-hydroxyvitamin-d-concentrations-in-women-treated-for-breast-cancer-participating-in-a-lifestyle-trial-in-italy">Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in Italy&lt;/a>&lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
&lt;/nav>
&lt;hr>
&lt;h4 id="post-diagnosis-serum-25-hydroxyvitamin-d-concentrations-in-women-treated-for-breast-cancer-participating-in-a-lifestyle-trial-in-italy">Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in Italy&lt;/h4>
&lt;p>Reumatismo 2024 Mar 22;76(1). &lt;a href="https://doi.org/10.4081/reumatismo.2024.1632">doi: 10.4081/reumatismo.2024.1632&lt;/a> Italy&lt;/p>
&lt;p>&lt;strong>Risks for those not supplementing with Vitamin D&lt;/strong>&lt;/p>
&lt;table>
 &lt;thead>
 &lt;tr>
 &lt;th>&lt;/th>
 &lt;th>&lt;/th>
 &lt;/tr>
 &lt;/thead>
 &lt;tbody>
 &lt;tr>
 &lt;td>BMI&lt;/td>
 &lt;td>Risk of &amp;lt;20 ng&lt;br>vs &amp;lt;25 kg/m2&lt;/td>
 &lt;/tr>
 &lt;tr>
 &lt;td>25-30&lt;/td>
 &lt;td>2.68 X&lt;/td>
 &lt;/tr>
 &lt;tr>
 &lt;td>&amp;gt;30&lt;/td>
 &lt;td>5.38 X&lt;/td>
 &lt;/tr>
 &lt;tr>
 &lt;td>≥35&lt;/td>
 &lt;td>7.08 X&lt;/td>
 &lt;/tr>
 &lt;/tbody>
&lt;/table>
&lt;p>Objective: To report cross-sectionally serum levels of 25-hydroxyvitamin D &lt;span>[25(OH)D]&lt;/span> in women living in Italy within 12 months from breast cancer (BC) diagnosis.&lt;/p></description></item><item><title>An activated Vitamin D Receptor fights Autoimmune Diseases, Infections, Cancers, etc.</title><link>//localhost:1313/posts/an-activated-vitamin-d-receptor-fights-autoimmune-diseases-infections-cancers-etc.html</link><pubDate>Sat, 13 Jan 2024 00:00:00 +0000</pubDate><guid>//localhost:1313/posts/an-activated-vitamin-d-receptor-fights-autoimmune-diseases-infections-cancers-etc.html</guid><description>&lt;nav id="TableOfContents">
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>&lt;a href="#methylation-of-the-vitamin-d-receptor-gene-in-human-disorders">Methylation of the Vitamin D Receptor Gene in Human Disorders&lt;/a>&lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
&lt;/nav>
&lt;hr>
&lt;h4 id="methylation-of-the-vitamin-d-receptor-gene-in-human-disorders">Methylation of the Vitamin D Receptor Gene in Human Disorders&lt;/h4>
&lt;p>Int. J. Mol. Sci. 2024, 25(1), 107; &lt;a href="https://doi.org/10.3390/ijms25010107">https://doi.org/10.3390/ijms25010107&lt;/a>&lt;/p>
&lt;p>by Beatrice Gasperini 1,†,Angela Falvino 1,†,Eleonora Piccirilli 2,Umberto Tarantino 2ORCID,Annalisa Botta 1,*ORCID and Virginia Veronica Visconti 1ORCID&lt;/p>
&lt;p>1 Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy&lt;/p>
&lt;p>2 Department of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy&lt;/p></description></item><item><title>Breast Cancer risk reduced if consume butyrate</title><link>//localhost:1313/posts/breast-cancer-risk-reduced-if-consume-butyrate.html</link><pubDate>Sat, 06 Jan 2024 00:00:00 +0000</pubDate><guid>//localhost:1313/posts/breast-cancer-risk-reduced-if-consume-butyrate.html</guid><description>&lt;nav id="TableOfContents">
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>
 &lt;ul>
 &lt;li>&lt;a href="#intestinal-vitamin-d-receptor-protects-against-extraintestinal-breast-cancer-tumorigenesis">Intestinal vitamin D receptor protects against extraintestinal breast cancer tumorigenesis&lt;/a>&lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
 &lt;/li>
 &lt;/ul>
&lt;/nav>
&lt;hr>
&lt;h4 id="intestinal-vitamin-d-receptor-protects-against-extraintestinal-breast-cancer-tumorigenesis">Intestinal vitamin D receptor protects against extraintestinal breast cancer tumorigenesis&lt;/h4>
&lt;p>Gut Microbes, 15:1,2202593, DOI: 10.1080/19490976.2023.2202593&lt;/p>
&lt;p>Yong-Guo Zhang, Yinglin Xia, Jilei Zhang, Shreya Deb, Shari Garrett &amp;amp; Jun Sun&lt;/p>
&lt;p>The microbiota plays critical roles in regulating the function and health of the intestine and extraintestinal organs. A fundamental question is whether an intestinal-microbiome-breast axis exists during the development of breast cancer. If so, what are the roles of host factors? Vitamin D receptor (VDR) involves host factors and the human microbiome. Vdr gene variation shapes the human microbiome, and VDR deficiency leads to dysbiosis. We hypothesized that intestinal VDR protects hosts against tumorigenesis in the breast. We examined a 7,12-dimethylbenzanthracene (DMBA)-induced breast cancer model in intestinal epithelial VDR knockout (VDRAIEC) &lt;strong>mice&lt;/strong> with dysbiosis. We reported that VDRAIEC &lt;strong>mice&lt;/strong> with dysbiosis are more susceptible to breast cancer induced by DMBA. Intestinal and breast microbiota analysis showed that VDR deficiency leads to a bacterial profile shift from normal to susceptible to carcinogenesis. We found enhanced bacterial staining within breast tumors. At the molecular and cellular levels, we identified the mechanisms by which intestinal epithelial VDR deficiency led to increased gut permeability, disrupted tight junctions, microbial translocation, and enhanced inflammation, thus increasing tumor size and number in the breast. Furthermore, treatment with the beneficial bacterial metabolite butyrate or the probiotic Lactobacillus plantarum reduced breast tumors, enhanced tight junctions, inhibited inflammation, increased butyryl-CoA transferase, and decreased levels of breast Streptococcus bacteria in VDRAIEC &lt;strong>mice&lt;/strong> . The gut microbiome contributes to the pathogenesis of diseases not only in the intestine but also in the breast. Our study provides insights into the mechanism by which intestinal VDR dysfunction and gut dysbiosis lead to a high risk of extraintestinal tumorigenesis. Gut-tumor-microbiome interactions represent a new target in the prevention and treatment of breast cancer.&lt;/p></description></item></channel></rss>